INSM - Insmed Incorporated
| Previous Close | 20.22 |
| Open | 20.23 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 19.51 - 20.30 |
| 52 Week Range | 15.33 - 33.13 |
| Volume | 1,070,796 |
| Avg. Volume | 958,216 |
| Market Cap | 1.795B |
| Beta (5Y Monthly) | 3.05 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.60 |
| Earnings Date | Feb 19, 2020 - Feb 23, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.56 |
- PR Newswire
Insmed to Present at the 38th Annual J.P. Morgan Healthcare Conference
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that Will Lewis, Chairman and Chief Executive Officer of Insmed, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 16, 2020 at 9:00 a.m. PT.
- PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the granting of inducement awards to seven new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.
- Simply Wall St.
Insmed Incorporated (NASDAQ:INSM): When Will It Breakeven?
Insmed Incorporated's (NASDAQ:INSM): Insmed Incorporated, a global biopharmaceutical company, focuses on the...
- Insider Monkey
Did Hedge Funds Drop The Ball On Insmed Incorporated (INSM) ?
"Since 2006, value stocks (IVE vs IVW) have underperformed 11 of the 13 calendar years and when they beat growth, it wasn't by much. Cumulatively, through this week, it has been a 122% differential (up 52% for value vs up 174% for growth). This appears to be the longest and most severe drought for value […]
- Thomson Reuters StreetEvents
Edited Transcript of INSM earnings conference call or presentation 30-Oct-19 12:30pm GMT
Q3 2019 Insmed Inc Earnings Call
- PR Newswire
Insmed Appoints Dr. Clarissa Desjardins to its Board of Directors and Names Roger Adsett Chief Operating Officer
BRIDGEWATER, N.J., Nov. 14, 2019 /PRNewswire/ -- Insmed Incorporated (INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Clarissa Desjardins, Ph.D., to its Board of Directors. Dr. Desjardins has more than 20 years of leadership experience in biotechnology, pharmaceuticals and research, and currently serves as President and Chief Executive Officer of Clementia Pharmaceuticals Inc., recently acquired by Ipsen S.A. Insmed also announced the promotion of Roger Adsett, the Company's Chief Commercial Officer, to Chief Operating Officer, effective immediately.
- PR Newswire
Insmed to Present at Two November Conferences
BRIDGEWATER, N.J. , Nov. 5, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today ...
- Simply Wall St.
Have Insiders Been Selling Insmed Incorporated (NASDAQ:INSM) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
- Zacks
Insmed (INSM) in Focus: Stock Moves 7.1% Higher
Insmed (INSM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Zacks
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -3.03% and 12.20%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
--ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $38.9 Million for the Third Quarter of 2019-- --Company Raises Full-Year 2019 ARIKAYCE Revenue Guidance to Range of $133 Million to ...
- Insider Monkey
Hedge Funds Are Getting Burned By Insmed Incorporated (INSM)
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Our research shows that most of the stocks that smart money likes historically generate strong risk-adjusted returns. […]
- PR Newswire
Insmed to Host Third Quarter 2019 Financial Results Conference Call on Wednesday, October 30, 2019
BRIDGEWATER, N.J. , Oct. 23, 2019 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
- Zacks
Implied Volatility Surging for Insmed (INSM) Stock Options
Investors need to pay close attention to Insmed (INSM) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of INSM earnings conference call or presentation 1-Aug-19 12:30pm GMT
Q2 2019 Insmed Inc Earnings Call
- Simply Wall St.
Insmed (NASDAQ:INSM) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
- PR Newswire
Insmed to Present at Two September Conferences
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
- Simply Wall St.
Volatility 101: Should Insmed (NASDAQ:INSM) Shares Have Dropped 28%?
The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...
Motley FoolInsmed (INSM) Q2 2019 Earnings Call Transcript
INSM earnings call for the period ending June 30, 2019.
- Motley Fool
Here’s Why Insmed Fell Hard Today
After a solid second quarter, investors in the biopharmaceutical company were left to wonder about management’s tepid growth forecast.
